Literature DB >> 22828912

Recent progress in mucosal vaccine development: potential and limitations.

Nils Lycke1.   

Abstract

Most pathogens access the body through the mucosal membranes. Therefore, effective vaccines that protect at these sites are much needed. However, despite early success with the live attenuated oral polio vaccine over 50 years ago, only a few new mucosal vaccines have been subsequently launched. This is partly due to problems with developing safe and effective mucosal adjuvants. In the past decade, however, the successful development of live attenuated mucosal vaccines against influenza virus and rotavirus infections has boosted interest in this field, and great expectations for new mucosal vaccines lie ahead. Here, I discuss the expanding knowledge and strategies used in the development of mucosal vaccines.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22828912     DOI: 10.1038/nri3251

Source DB:  PubMed          Journal:  Nat Rev Immunol        ISSN: 1474-1733            Impact factor:   53.106


  153 in total

1.  CD11c(high )dendritic cells are essential for activation of CD4+ T cells and generation of specific antibodies following mucosal immunization.

Authors:  Linda Fahlén-Yrlid; Tobias Gustafsson; Jessica Westlund; Anna Holmberg; Anna Strömbeck; Margareta Blomquist; Gordon G MacPherson; Jan Holmgren; Ulf Yrlid
Journal:  J Immunol       Date:  2009-09-28       Impact factor: 5.422

Review 2.  Oral vaccines against cholera.

Authors:  Sunheang Shin; Sachin N Desai; Binod K Sah; John D Clemens
Journal:  Clin Infect Dis       Date:  2011-04-14       Impact factor: 9.079

Review 3.  Sublingual mucosa: A new vaccination route for systemic and mucosal immunity.

Authors:  Mi-Na Kweon
Journal:  Cytokine       Date:  2011-01-15       Impact factor: 3.861

4.  Maximal adjuvant activity of nasally delivered IL-1α requires adjuvant-responsive CD11c(+) cells and does not correlate with adjuvant-induced in vivo cytokine production.

Authors:  Afton L Thompson; Brandi T Johnson; Gregory D Sempowski; Michael D Gunn; Baidong Hou; Anthony L DeFranco; Herman F Staats
Journal:  J Immunol       Date:  2012-02-15       Impact factor: 5.422

5.  Evaluation of Salmonella enterica serovar Typhi (Ty2 aroC-ssaV-) M01ZH09, with a defined mutation in the Salmonella pathogenicity island 2, as a live, oral typhoid vaccine in human volunteers.

Authors:  B D Kirkpatrick; Robin McKenzie; J Patrick O'Neill; Catherine J Larsson; A Louis Bourgeois; Janet Shimko; Matthew Bentley; Jill Makin; Steve Chatfield; Zoë Hindle; Christine Fidler; Brad E Robinson; Cassandra H Ventrone; Nivedita Bansal; Colleen M Carpenter; Deborah Kutzko; Sandra Hamlet; Casey LaPointe; David N Taylor
Journal:  Vaccine       Date:  2005-08-18       Impact factor: 3.641

6.  Enhanced humoral and cellular immune responses after sublingual immunization against human papillomavirus 16 L1 protein with adjuvants.

Authors:  Hee-Jeong Cho; Ji-Yeon Kim; Young Lee; Jung Mogg Kim; Young Bong Kim; Taehoon Chun; Yu-Kyoung Oh
Journal:  Vaccine       Date:  2010-01-28       Impact factor: 3.641

Review 7.  Methods for evaluation of humoral immune responses in human genital tract secretions.

Authors:  Jiri Mestecky; Rashada C Alexander; Qing Wei; Zina Moldoveanu
Journal:  Am J Reprod Immunol       Date:  2010-11-19       Impact factor: 3.886

8.  A truncated form of HpaA is a promising antigen for use in a vaccine against Helicobacter pylori.

Authors:  Carl-Fredrik Flach; Natascha Svensson; Margareta Blomquist; Annelie Ekman; Sukanya Raghavan; Jan Holmgren
Journal:  Vaccine       Date:  2010-12-13       Impact factor: 3.641

Review 9.  Immunogenicity and efficacy of oral vaccines in developing countries: lessons from a live cholera vaccine.

Authors:  Myron M Levine
Journal:  BMC Biol       Date:  2010-10-04       Impact factor: 7.431

10.  Intestinal CD103+, but not CX3CR1+, antigen sampling cells migrate in lymph and serve classical dendritic cell functions.

Authors:  Olga Schulz; Elin Jaensson; Emma K Persson; Xiaosun Liu; Tim Worbs; William W Agace; Oliver Pabst
Journal:  J Exp Med       Date:  2009-12-14       Impact factor: 14.307

View more
  248 in total

1.  Nanoformulation of synergistic TLR ligands to enhance vaccination against Entamoeba histolytica.

Authors:  Mayuresh M Abhyankar; Zannatun Noor; Mark A Tomai; James Elvecrog; Christopher B Fox; William A Petri
Journal:  Vaccine       Date:  2017-01-12       Impact factor: 3.641

2.  Novel chimpanzee adenovirus-vectored respiratory mucosal tuberculosis vaccine: overcoming local anti-human adenovirus immunity for potent TB protection.

Authors:  M Jeyanathan; N Thanthrige-Don; S Afkhami; R Lai; D Damjanovic; A Zganiacz; X Feng; X-D Yao; K L Rosenthal; M Fe Medina; J Gauldie; H C Ertl; Z Xing
Journal:  Mucosal Immunol       Date:  2015-04-15       Impact factor: 7.313

3.  Self-adjuvanting C18 lipid vinil sulfone-PP2A vaccine: study of the induced immunomodulation against Trichuris muris infection.

Authors:  M Gomez-Samblas; J J García-Rodríguez; M Trelis; D Bernal; F J Lopez-Jaramillo; F Santoyo-Gonzalez; S Vilchez; A M Espino; F Bolás-Fernández; A Osuna
Journal:  Open Biol       Date:  2017-04       Impact factor: 6.411

4.  Modern Vaccine Adjuvant/Formulation--Session 9: Adjuvants.

Authors:  François Dalençon
Journal:  Hum Vaccin Immunother       Date:  2013-08-12       Impact factor: 3.452

Review 5.  Microneedle-Mediated Vaccine Delivery to the Oral Mucosa.

Authors:  Rachel L Creighton; Kim A Woodrow
Journal:  Adv Healthc Mater       Date:  2018-12-10       Impact factor: 9.933

6.  Self-encapsulating Poly(lactic-co-glycolic acid) (PLGA) Microspheres for Intranasal Vaccine Delivery.

Authors:  Brittany A Bailey; Kashappa-Goud H Desai; Lukasz J Ochyl; Susan M Ciotti; James J Moon; Steven P Schwendeman
Journal:  Mol Pharm       Date:  2017-08-22       Impact factor: 4.939

7.  From allergen to oral vaccine carrier: A new face of ragweed pollen.

Authors:  Md Jasim Uddin; Harvinder Singh Gill
Journal:  Int J Pharm       Date:  2018-05-03       Impact factor: 5.875

Review 8.  Current state and challenges in developing oral vaccines.

Authors:  Julia E Vela Ramirez; Lindsey A Sharpe; Nicholas A Peppas
Journal:  Adv Drug Deliv Rev       Date:  2017-04-22       Impact factor: 15.470

9.  Mucosal microbial parasites/symbionts in health and disease: an integrative overview.

Authors:  Robert P Hirt
Journal:  Parasitology       Date:  2019-08       Impact factor: 3.234

10.  Oral Biologic Delivery: Advances Toward Oral Subunit, DNA, and mRNA Vaccines and the Potential for Mass Vaccination During Pandemics.

Authors:  Jacob William Coffey; Gaurav Das Gaiha; Giovanni Traverso
Journal:  Annu Rev Pharmacol Toxicol       Date:  2020-08-31       Impact factor: 13.820

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.